Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03496012 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT03496012 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 169 participants.
The verdict
NCT03496012, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the efficacy and safety of a single sub-retinal injection of BIIB111 in participants with choroideremia (CHM).
Interventions
- GENETIC BIIB111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03496012
The ClinicalTrials.gov registry entry for NCT03496012 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIB111 is the first listed.
NCT03496012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03496012 about?
NCT03496012 is a clinical study titled "Efficacy and Safety of BIIB111 for the Treatment of Choroideremia". The objective of the study is to evaluate the efficacy and safety of a single sub-retinal injection of BIIB111 in participants with choroideremia (CHM).
What is the current status of trial NCT03496012?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2017-12-11. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT03496012?
The interventions under investigation include: BIIB111 (GENETIC).
Who is sponsoring clinical trial NCT03496012?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.